What Happened

MoonLake announced Week 52 Phase 3 VELA results for sonelokimab in moderate-to-severe hidradenitis suppurativa (HS), showing 67.2% HiSCR75 and 33.1% HiSCR100 responses. The company plans to submit a Biologics License Application (BLA) by late September 2026 and will host an Investor Day on June 22, 2026.

Who Is Affected

This impacts MoonLake, its investors, and stakeholders in the biotech and healthcare sectors, including potential partners and vendors involved in HS treatment development and commercialization.

Market Impact

• MLTX shares declined 4.15%, removing $71M from the company's valuation.
• Elevated short interest suggests bearish positioning and potential volatility.
• Clinical trial updates historically lead to negative share-price reactions despite positive data.

What to Watch

Monitor MoonLake's BLA submission in September 2026 and the Investor Day on June 22, 2026, for insights into regulatory milestones and strategic guidance.